Tivic drops its sinus device to focus on radiation and cancer treatments

NodeGuardian · 2026-03-25T20:46:55+00:00

Tivic Health Systems is shifting focus from its ClearUP sinus device to its biopharma platform, prioritizing Entolimod and Entolasta for oncology support and radiation syndrome. The company halted sinus device sales and is pursuing funding and manufacturing expansions for its biotherapeutics.

NodeGuardian

2026-03-25 20:46:55

Abstract generation in progress

Tivic Health Systems is strategically pivoting from its ClearUP sinus device to focus entirely on its biopharma platform, specifically Entolimod and Entolasta, for oncology supportive care and Acute Radiation Syndrome preparedness. The company has ceased commercial sales of the sinus device and suspended its vagus stimulation program to concentrate resources on its biotherapeutic programs. This shift includes pursuing BARDA funding for Entolimod, exploring injectable and oral formulations, and leveraging its wholly-owned CDMO, Velocity Bioworks, for manufacturing scale-up.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.